Methods for treating myc-amplified cancer
AssigneesThe Governing Council of the University of Toronto, McMaster University
InventorsJason Moffat, Jose Rafael Montenegro Burke, Sheila K. Singh, William D. Gwynne, Chitra Venugopal
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the treatment of a myc-amplified cancer using a DHODH inhibitor. Also disclosed herein are combination therapies, compositions and kits for the treatment of a myc-amplified cancer comprising a DHODH inhibitor.
Claims23
A method of treating a myc-amplified cancer comprising administering a dihydroorotate dehydrogenase (DHODH) inhibitor, to a subject in need thereof, wherein the myc-amplified cancer is not acute myeloid leukemia (AML).
A method of treating a myc-amplified cancer in a subject comprising administering a dihydroorotate dehydrogenase (DHODH) inhibitor to a subject in need thereof, wherein the myc-amplified cancer has increased pyrimidine and/or purine metabolites relative to a non-cancerous control, wherein the cancer is not acute myeloid leukemia (AML).
A method of selecting a therapy for treating a myc-amplified cancer in a subject comprising:
- a) obtaining a biopsy of the myc-amplified cancer;
- b) detecting increased pyrimidine and/or purine metabolites in the biopsy;
- and
- c) selecting a dihydroorotate dehydrogenase (DHODH) inhibitor for treating the subject when there is an increased level of pyrimidine and/or purine metabolites in the biopsy, wherein the cancer is not acute myeloid leukemia (AML).
Dependencies are inferred from the claim text.